Strategic Asset Sale Xbrane recently sold assets to Alvotech for approximately $27.4 million, indicating a focus on optimizing its portfolio and possibly looking for partnership opportunities to leverage its core biosimilar development capabilities.
R&D Focus The company's sale of research and development operations to Alvotech and ongoing development of biosimilars like Nivolumab reflect a commitment to innovation, presenting opportunities to support their pipeline growth through scientific partnerships and technology collaborations.
Financial Support With recent funding of $1.8 million from major shareholders and a short-term loan from Systematic Group, Xbrane shows active efforts to secure capital, making it receptive to financial solutions, grants, or strategic investments that can boost its R&D and commercial activities.
Market Expansion Challenges Xbrane's recent issues with a North American ranibizumab partner suggest potential barriers in market penetration, highlighting opportunities for sales in biosimilar distribution, licensing, or partnership negotiations in North America.
Focus on Cost Optimization The company's implementation of a cost-savings scheme signifies an emphasis on operational efficiency, creating potential openings for sales solutions that enhance manufacturing, logistics, and cost management tools tailored to biotech innovators.
Xbrane Biopharma AB uses 8 technology products and services including Microsoft 365, Font Awesome, TweenMax, and more. Explore Xbrane Biopharma AB's tech stack below.
| Xbrane Biopharma AB Email Formats | Percentage |
| First.Last@xbrane.com | 45% |
| First@xbrane.com | 5% |
| First.Last@xbrane.com | 45% |
| First@xbrane.com | 5% |
Biotechnology ResearchStockholm, Sweden11-50 Employees
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
Company Overview
Media & News
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com